Next Frontier of Cardiovascular Innovation

Panelists

Dr. Ena Oru

Executive Director- Cardiometabolic Research, Early phase at Eli Lilly and Company

Ena is a physician and Executive Director at Eli Lilly and Company. His work focuses on advancing the development of medicines for the treatment of diabetes and its related complications, obesity and atherosclerotic cardiovascular disease.

Prior to Lilly, he worked with several countries on policies and mechanisms to improve access to new-to-market diagnostics and treatments for HIV and Hepatitis C, first at the Clinton Health Access Initiative in Nigeria and then at World Health Organization (WHO) in Switzerland. He was also a Fellow of Health and Life Sciences at Gates Ventures.

Outside his MBA from MIT, Ena holds a master’s in public health from Columbia University, and a medical degree from Windsor University. He is based in New York.

Dr. Shyamal Patel

Head of Science, Oura

Shyamal Patel is the Head of Science at ŌURA where he leads an interdisciplinary organization focused on research and development of algorithms that translate sensor data into accurate measures of health and wellbeing. He is passionate about building digital health solutions that enable the transformation of healthcare from a largely subjective, episodic and reactive model to become more objective, continuous and proactive. Before ŌURA, Shyamal led data science teams in several startups and most recently at Pfizer where his work was focused on development, validation and deployment of new digital endpoints across multiple therapeutic areas in regulated clinical trials. Shyamal has a PhD in electrical engineering with a specialization in signal processing and applied machine learning from Northeastern University. He completed his post-doctoral research at Harvard University and lives in Boston.

Glen Fantuzzi

GM, Digital Patient Solutions at Johnson & Johnson MedTech - Heart Recovery

Glen Fantuzzi is the General Manager of Digital Patient Solutions at Abiomed, where he leads AI-enabled strategy and commercialization around the company’s heart pump platform and a growing ecosystem of connected cardiovascular technologies. His work focuses on integrating digital tools and intelligent systems to enhance clinical decision-making, expand patient monitoring, and improve outcomes in acute cardiac care.

With deep MedTech leadership experience, Glen operates at the intersection of innovation, operations, and patient-centered care, helping scale transformative technologies in complex healthcare markets. At MIT Sloan’s healthcare conference, he will share perspectives on the future of AI-driven cardiovascular care and the role of digital ecosystems in advancing next-generation heart recovery.

Dr. Cecilie Heerdegen Jepsen

VP, R&D External Innovation and Assessment at Novo Nordisk

Cecilie Heerdegen Jepsen is Head of R&D External Innovation and Assessment at Novo Nordisk, where she leads the evaluation and integration of external scientific and translational opportunities across the R&D portfolio. With more than a decade at Novo Nordisk, she has held senior leadership roles spanning external innovation, translational medicine, precision medicine, biomarkers, and global medical affairs, with a strong focus on cardiometabolic and obesity-related diseases.

Cecilie is a physician-scientist with prior research training at Harvard University, Massachusetts General Hospital, and the University of Copenhagen, bringing a deep perspective on bridging academic discovery and industry-led cardiovascular innovation.

Moderator

Dr. Priyanka Bobbili

VP at Analysis Group

Dr. Bobbili specializes in the application of statistical methods to the causal analysis of complex longitudinal data. She has a wide range of experience in epidemiology and outcomes research, including studies on causal methods, drug adherence, and comparative effectiveness, particularly in the oncology disease area.

Dr. Bobbili has experience designing and conducting studies using large observational and real-world data (RWD) sources to emulate target trials. She has been involved in several studies to support US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory submissions, particularly regulatory-grade real-world studies for new indications, as well as label expansions and historical control studies to help contextualize the results of clinical trials. Her work has been presented at multiple conferences and published in numerous peer-reviewed journals.

Prior to joining Analysis Group, Dr. Bobbili served as a research assistant and teaching assistant at the Harvard T. H. Chan School of Public Health.